BeOne Medicines Ltd. Enters Material Definitive Agreement

TL;DR

BeOne Medicines just signed a big deal, could be a game-changer.

AI Summary

BeOne Medicines Ltd. announced on August 25, 2025, that it entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company, formerly known as BeiGene, Ltd. until August 19, 2015, is based in Basel, Switzerland.

Why It Matters

This filing signals a significant new contract or financial commitment for BeOne Medicines Ltd., potentially impacting its future operations and financial standing.

Risk Assessment

Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to the terms of the agreement and the company's ability to meet them.

Key Players & Entities

• BeOne Medicines Ltd. (company) — Registrant
• August 25, 2025 (date) — Date of Report
• BeiGene, Ltd. (company) — Former Company Name
• August 19, 2015 (date) — Date of Name Change
• Basel, Switzerland (location) — Company Headquarters

FAQ

Key Financial Figures

• $0.0001 — resenting 13 Ordinary Shares, par value $0.0001 per share ONC The NASDAQ Global Selec
• $885 million — , in exchange for an upfront payment of $885 million to be paid to the Seller at closing, Ro
• $65 m — l portion of Royalty Payments for up to $65 million, subject to proportional adjustme
• $1.5 billion — al Imdelltra ex-China Net Revenue above $1.5 billion. In addition to retaining the rights to
• $950 Million — RA Royalty Purchase Agreement for up to $950 Million" issued by BeOne Medicines Ltd. on Augu

Filing Documents

• bgne-20250825.htm (8-K) — 45KB
• a20250825formxprojecttarot.htm (EX-99.1) — 16KB
• image_0.jpg (GRAPHIC) — 44KB
• 0001628280-25-041082.txt ( ) — 243KB
• bgne-20250825.xsd (EX-101.SCH) — 2KB
• bgne-20250825_lab.xml (EX-101.LAB) — 21KB
• bgne-20250825_pre.xml (EX-101.PRE) — 12KB
• bgne-20250825_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On August 25, 2025, BeOne Medicines Ltd. (the "Company"), BeOne Medicines I GmbH (the "Seller"), a subsidiary of the Company, and Royalty Pharma Investments 2023 ICAV ("Royalty Pharma") entered into a Royalty Purchase Agreement (the "Royalty Purchase Agreement"). Pursuant to the Royalty Purchase Agreement, in exchange for an upfront payment of $885 million to be paid to the Seller at closing, Royalty Pharma purchased from the Seller a significant portion of the Seller's rights to receive certain tiered mid-single digit royalty payments (the "Royalty Payments") based on annual net revenue from sales outside of China ("Imdelltra ex-China Net Revenue") of any and all products that consist of the monoclonal antibody Imdelltra (tarlatamab), in any strengths, forms (including pegylated versions), formulations (whether short-acting or long-acting), administrations or delivery routes (collectively, "Imdelltra Products"). Such Royalty Payments are payable to the Seller by Amgen Inc. ("Amgen") under the Collaboration Agreement dated October 31, 2019 (as amended from time to time, the "Amgen Collaboration Agreement"), by and between the Company, the Seller and Amgen. In addition, from the closing to August 25, 2026, the Seller will have the option (the "Put Option"), in its sole discretion, to sell to Royalty Pharma an additional portion of Royalty Payments for up to $65 million, subject to proportional adjustments based on the value of such additional portion of the Royalty Payments. The Seller will share in a portion of the Royalty Payments on annual Imdelltra ex-China Net Revenue above $1.5 billion. In addition to retaining the rights to the Royalty Payments as described above, the Seller has retained its other economic interests under the Amgen Collaboration Agreement. Shortly after closing, Royalty Pharma, the Seller and an escrow agent will execute an escrow agreement to establish an escrow account (the "Escrow

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 25, 2025, the Company issued a press release announcing entry into the Royalty Purchase Agreement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report. The information furnished under Item 7.01 of this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the total amount of proceeds that BeOne will receive under the Royalty Purchase Agreement, the establishment of the Escrow Account, the Seller's option to sell additional Royalty Payments, the anticipated benefits of the Royalty Purchase Agreement, and the anticipated accounting treatment. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information herein is as of the date set forth above, and BeOne undertakes no duty to update such information unles

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release titled "BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million" issued by BeOne Medicines Ltd. on August 25, 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Exhibit Index Exhibit No. Description 99.1 Press release titled "BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million" issued by BeOne Medicines Ltd. on August 25, 2025 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BEONE MEDICINES LTD. Date: August 25, 2025 By: /s/ Chan Lee Name: Chan Lee Title: Senior Vice President, General Counsel

View Full Filing

View this 8-K filing on SEC EDGAR